nach oben

Journal of Neurology

Erschienen in:

01.06.2013 | Medical Progress in the Journal of Neurology

Emerging issues in acute ischemic stroke

verfasst von: Xabier Urra, Ángel Chamorro

Erschienen in: Journal of Neurology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

In this update we review studies on a wide range of topics, from diagnostic aspects of acute stroke to the clinical implications of the complex interaction between the brain and the immune system. Recent randomized trials and observational studies have reinforced the effectiveness of intravenous thrombolysis with t-PA in patients that qualify for this treatment, including patients presenting with mild symptoms or on subtherapeutic oral anticoagulation. Despite all the negative studies on the endovascular treatment of acute stroke, the utility of newer mechanical thrombectomy devices in patients with stroke and large vessel occlusion is being assessed in ongoing clinical trials. In addition to the various revascularization therapies that have a limited time window, treatments aimed at protecting the neurovascular unit may be used in more patients if their efficacy is confirmed in humans, and experimental studies suggest that the modulation of specific aspects of the immune system may increase the likelihood of successful recovery after cerebral ischemia.

Hom J, Dankbaar JW, Soares BP, Schneider T, Cheng SC, Bredno J, Lau BC, Smith W, Dillon WP, Wintermark M (2011) Blood-brain barrier permeability assessed by perfusion CT predicts symptomatic hemorrhagic transformation and malignant edema in acute ischemic stroke. AJNR Am J Neuroradiol 32:41–48PubMedCrossRef

Desilles JP, Rouchaud A, Labreuche J, Meseguer E, Laissy JP, Serfaty JM, Lapergue B, Klein IF, Guidoux C, Cabrejo L, Sirimarco G, Lavallée PC, Schouman-Claeys E, Amarenco P, Mazighi M (2013) Blood-brain barrier disruption is associated with increased mortality after endovascular therapy. Neurology 80:844–851PubMedCrossRef

Walter S, Kostopoulos P, Haass A, Keller I, Lesmeister M, Schlechtriemen T, Roth C, Papanagiotou P, Grunwald I, Schumacher H, Helwig S, Viera J, Körner H, Alexandrou M, Yilmaz U, Ziegler K, Schmidt K, Dabew R, Kubulus D, Liu Y, Volk T, Kronfeld K, Ruckes C, Bertsch T, Reith W, Fassbender K (2012) Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol 11:397–404. doi:10.1016/S1474-4422(12)70057-1 PubMedCrossRef

Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, Mustanoja S, Kuzmanovic I, Sairanen T, Forss N, Cordier M, Lyrer P, Kaste M, Tatlisumak T (2012) Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol 71:634–641PubMedCrossRef

Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED (2012) Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 307:2600–2608PubMedCrossRef

Urra X, Ariño H, Llull L, Amaro S, Obach V, Cervera A, Chamorro A (2013) The outcome of patients with mild stroke improves after treatment with systemic thrombolysis. PLoS ONE 8:e59420. doi:10.1371/journal.pone.0059420 PubMedCrossRef

IST-3 Collaborative Group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379:2352–2363PubMedCrossRef

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O’Brien B, Bladin C, McElduff P, Allen C, Bateman G, Donnan G, Davis S, Levi C (2012) A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 366:1099–1107PubMedCrossRef

Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella JRTR, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA, The Interventional Management of Stroke (IMS) III Investigators (2013) Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 368:893–903PubMedCrossRef

10.

Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, Boccardi E, The SYNTHESIS Expansion Investigators (2013) Endovascular treatment for acute ischemic stroke. N Engl J Med 368:904–913PubMedCrossRef

11.

Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, Wilder MJ, Lutsep HL, Czartoski TJ, Bernstein RA, Chang CW, Warach S, Fazekas F, Inoue M, Tipirneni A, Hamilton SA, Zaharchuk G, Marks MP, Bammer R, Albers GW, DEFUSE 2 Study Investigators (2012) MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. Lancet Neurol 11:860–867PubMedCrossRef

12.

Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH, Yoo AJ, Marshall RS, Meyers PM, Yavagal DR, Wintermark M, Guzy J, Starkman S, Saver JL, The MR RESCUE Investigators (2013) A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 368:914–923PubMedCrossRef

13.

Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, Clark W, Budzik R, Zaidat OO, for the SWIFT Trialists (2012) Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 380:1241–1249PubMedCrossRef

14.

Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, Liebeskind DS, Smith WS, for the TREVO 2 Trialists (2012) Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 380:1231–1240PubMedCrossRef

15.

Amaro S, Chamorro Á (2011) Translational stroke research of the combination of thrombolysis and antioxidant therapy. Stroke 42:1495–1499PubMedCrossRef

16.

Zinkstok SM, Roos YB, on behalf of the ARTIS Investigators (2012) Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. Lancet 380:731–737PubMedCrossRef

17.

Amaro S, Cánovas D, Castellanos M, Gállego J, Martí-Fábregas J, Segura T, Chamorro A (2010) The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rt-PA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke 5:325–328PubMedCrossRef

18.

Amaro S, Urra X, Gómez-Choco M, Obach V, Cervera A, Vargas M, Torres F, Rios J, Planas AM, Chamorro A (2011) Uric acid levels are relevant in patients with stroke treated with thrombolysis. Stroke 42:S28–S32PubMedCrossRef

19.

Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A (2007) A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 38:2173–2175PubMedCrossRef

20.

Amaro S, Obach V, Cervera A, Urra X, Gómez-Choco M, Planas AM, Chamorro A (2009) Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol 256:651–656PubMedCrossRef

21.

van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR (2007) Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 130:3063–3074PubMedCrossRef

22.

Silasi G, Klahr AC, Hackett MJ, Auriat AM, Nichol H, Colbourne F (2012) Prolonged therapeutic hypothermia does not adversely impact neuroplasticity after global ischemia in rats. J Cereb Blood Flow Metab 32:1525–1534PubMedCrossRef

23.

van der Worp HB, Macleod MR, Kollmar R, European Stroke Research Network for Hypothermia (EuroHYP) (2010) Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab 30:1079–1093. doi:10.1038/jcbfm.2010.44 PubMedCrossRef

24.

Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J, Cobo E, Secades JJ, International Citicoline Trial on acUte Stroke (ICTUS) Trial Investigators (2012) Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 380:349–357PubMedCrossRef

25.

Cook DJ, Teves L, Tymianski M (2012) Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature 483:213–217PubMedCrossRef

26.

Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, Milot G, Clark WM, Macdonald RL, Kelly ME, Boulton M, Fleetwood I, McDougall C, Gunnarsson T, Chow M, Lum C, Dodd R, Poublanc J, Krings T, Demchuk AM, Goyal M, Anderson R, Bishop J, Garman D, Tymianski M, ENACT Trial Investigators (2012) Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double blind, placebo-controlled trial. Lancet Neurol 11:942–950PubMedCrossRef

27.

Kaste M (2012) Is the door open again for neuroprotection trials in stroke? Lancet Neurol 11:930–931PubMedCrossRef

28.

Chamorro Á, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R (2012) The immunology of acute stroke. Nat Rev Neurol 8:401–410PubMedCrossRef

29.

Planas AM, Gómez-Choco M, Urra X, Gorina R, Caballero M, Chamorro Á (2012) Brain-derived antigens in lymphoid tissue of patients with acute stroke. J Immunol 188:2156–2163PubMedCrossRef

30.

Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM, Hadwin J, Carter KT, Shibata D, Cain KC (2011) Autoimmune responses to the brain after stroke are associated with worse outcome. Stroke 42:2763–2769. doi:10.1161/STROKEAHA.111.619593 PubMedCrossRef

31.

Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T, Ooboshi H, Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishibori M, Kuroda K, Akira S, Miyake K, Yoshimura A (2012) Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Nat Med 18:911–917PubMedCrossRef

32.

Gliem M, Mausberg AK, Lee JI, Simiantonakis I, van Rooijen N, Hartung HP, Jander S (2012) Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol 71:743–752. doi:10.1002/ana.23529 PubMedCrossRef

33.

Misra V, Ritchie MM, Stone LL, Low WC, Janardhan V (2012) Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy. Neurology 79:S207–S212PubMedCrossRef

34.

Oki K, Tatarishvili J, Wood J, Koch P, Wattananit S, Mine Y, Monni E, Tornero D, Ahlenius H, Ladewig J, Brüstle O, Lindvall O, Kokaia Z (2012) Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells 30:1120–1133PubMedCrossRef

35.

Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C, Tusche MW, Pavlov VA, Andersson U, Chavan S, Mak TW, Tracey KJ (2011) Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 334:98–101. doi:10.1126/science.1209985 PubMedCrossRef

Titel: Emerging issues in acute ischemic stroke
verfasst von: Xabier Urra
Ángel Chamorro
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Journal of Neurology / Ausgabe 6/2013
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-013-6919-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Faciobrachial dystonic seizures arise from cortico–subcortical abnormal brain areas

Risk of multiple sclerosis following clinically isolated syndrome: a 4-year prospective study

Examination of cardiovascular and peripheral autonomic function in the ICU: a pilot study

A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene

Generalized myoclonus as a prominent symptom in a patient with FTLD-TDP